Nova Leap Health Corp. Announces Expansion in Nova Scotia With Execution of Definitive Agreement and Provides Update on Florida Acquisition

In This Article:

Nova Leap Health Corp.
Nova Leap Health Corp.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

HALIFAX, Nova Scotia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the “Agreement”) to acquire all of the shares of two affiliated home care services companies (“the Targets”) with operations in Nova Scotia (the “Transaction”). The Targets reported aggregate unaudited revenue of approximately $2.56 million, unaudited net income of approximately $235,000 and Adjusted EBITDA of approximately $276,000 for the 2023 fiscal year. All amounts are in Canadian Dollars (“CAD”) unless otherwise specified.

Under the terms of the Agreement, the Transaction is to be made for total consideration of $1,380,000, on a cash-free, debt-free basis and subject to customary post-closing working capital adjustments, with the full amount payable in cash on closing. The $1,380,000 purchase price will be funded by way of a debt facility with the Company’s lender and is repayable over a five-year term.

“As mentioned in previous shareholder communications, we have been actively working on acquisition opportunities since re-engaging our M&A program,” said Dana Hatfield, Chair of the Board of Nova Leap. “This acquisition allows us to expand our geographical coverage within the province with the addition of two new territories.”

The Transaction is a Non-Arm’s Length transaction pursuant to TSX Venture Exchange (“TSXV”) policies, as the vendors are controlled by Chris Dobbin, a Director, CEO and significant shareholder of Nova Leap, and the Estate of Wayne Fulcher, a shareholder with more than 10% of the outstanding shares of Nova Leap. In addition, Jill Dobbin, an officer of certain subsidiaries of Nova Leap, is also an officer of the Targets. The Transaction is also a related party transaction pursuant to Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions (“MI 61-101”). However, Nova Leap is exempt from the valuation and minority approval requirements in MI 61-101 as the fair market value of the shares to be acquired by Nova Leap and the purchase price payable does not exceed 25% of its market capitalization.

Completion of the Transaction is subject to the satisfaction of certain conditions, including the approval of the TSXV and lender approval. The Transaction also requires the approval of disinterested shareholders of the Company, to be sought at a meeting of the shareholders which is expected to be held in December.